Core Viewpoint - The collaboration between Shanghai Ruizhi Pharmaceutical Research Group and East China Normal University aims to advance drug discovery and delivery systems through the establishment of a cutting-edge technology joint laboratory, focusing on antibody-drug conjugates (ADC) and nucleotide monomer synthesis systems [1] Group 1: Collaboration and Research Focus - The partnership is based on a strategic cooperation framework agreement, emphasizing joint research in drug discovery, biochips, drug delivery systems, and drug conjugates [1] - The newly developed automated, intelligent, and integrated desktop synthesis systems for ADC and nucleotide monomers enable seamless transition from laboratory research to industrial production [1] Group 2: Technological Advancements - The ADC microfluidic manufacturing system integrates ultra-fast laser microfluidic chips with intelligent process control, transitioning antibody drug conjugation from intermittent operations to platform-based manufacturing [1] - The nucleotide monomer microfluidic synthesis system utilizes a catalyst-free and base-free "intelligent microfluidic" approach for the continuous, stable, and green synthesis of phosphoramidite monomers, establishing new standards for the supply of nucleic acid drug materials [1] Group 3: Impact on R&D Efficiency - The implementation of these automated and intelligent synthesis systems is expected to significantly shorten research and development cycles and enhance R&D efficiency, ultimately providing better services to clients [1]